S100P is Overexpressed in Squamous Cell and Adenosquamous Carcinoma Subtypes of Endometrial Cancer and Promotes Cancer Cell Proliferation and Invasion

References

• Stewart BW, Wild CP. World Cancer Report 2014. Geneva; World Health Organization: 2014.
   Google Scholar
• Sorosky JI. Endometrial cancer. Obstet Gynecol 2012;120(2 Pt 1):383–397.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Choi HJ. Primary endometrial squamous cell carcinoma: a case report and review of relevant literature on korean women. Korean J Pathol 2012;46(4):395–398.
   PubMedGoogle Scholar
• Kilgore JE, Jackson AL, Ko EM, Soper JT, Van Le L, Gehrig PA, et al. Recurrence-free and 5-year survival following robotic-assisted surgical staging for endometrial carcinoma. Gynecol Oncol 2013;129(1):49–53.
   PubMed Web of Science ®Google Scholar
• Sakamoto A, Hirai Y, Yamauchi K, Kitagawa T, Sugano H, Masubuchi K, et al. Histology and prognosis of endometrial carcinoma. Gan No Rinsho 1987;33(15):1897–1900.
   PubMedGoogle Scholar
• Zaino RJ, Kurman RJ. Squamous differentiation in carcinoma of the endometrium: a critical appraisal of adenoacanthoma and adenosquamous carcinoma. Semin Diagn Pathol 1988;5(2):154–171.
   PubMed Web of Science ®Google Scholar
• Emoto Y, Kobayashi R, Akatsuka H, Hidaka H. Purification and characterization of a new member of the S-100 protein family from human placenta. Biochem Biophys Res Commun 1992;182(3):1246–1253.
   PubMed Web of Science ®Google Scholar
• Becker T, Gerke V, Kube E, Weber K. S100P, a novel Ca(2+)-binding protein from human placenta. cDNA cloning, recombinant protein expression and Ca2+ binding properties. Eur J Biochem 1992;207(2):541–547.
   PubMedGoogle Scholar
• Kretsinger RH. Calcium-binding proteins. Annu Rev Biochem 1976;45:239–266.
   PubMed Web of Science ®Google Scholar
• Chazin WJ. Releasing the calcium trigger. Nat Struct Biol 1995;2(9):707–710.
   PubMedGoogle Scholar
• Cancemi P, Di Cara G, Albanese NN, Costantini F, Marabeti MR, Musso R, et al. Large-scale proteomic identification of S100 proteins in breast cancer tissues. BMC Cancer 2010;10:476.
   PubMed Web of Science ®Google Scholar
• Eckert RL, Broome AM, Ruse M, Robinson N, Ryan D, Lee K. S100 proteins in the epidermis. J Invest Dermatol 2004;123(1):23–33.
   PubMed Web of Science ®Google Scholar
• Tutar Y. Dimerization and ion binding properties of S100P protein. Protein Pept Lett 2006;13(3):301–306.
   PubMed Web of Science ®Google Scholar
• Streicher WW, Lopez MM, Makhatadze GI. Modulation of quaternary structure of S100 proteins by calcium ions. Biophys Chem 2010;151(3):181–186.
   PubMed Web of Science ®Google Scholar
• Gibadulinova A, Tothova V, Pastorek J, Pastorekova S. Transcriptional regulation and functional implication of S100P in cancer. Amino Acids 2011;41(4):885–892.
   PubMed Web of Science ®Google Scholar
• Arumugam T, Simeone DM, Schmidt AM, Logsdon CD. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem 2004;279(7):5059–5065.
   PubMed Web of Science ®Google Scholar
• Jiang H, Hu H, Tong X, Jiang Q, Zhu H, Zhang S. Calcium-binding protein S100P and cancer: mechanisms and clinical relevance. J Cancer Res Clin Oncol 2012;138(1):1–9.
   PubMed Web of Science ®Google Scholar
• Guerreiro Da Silva ID, Hu YF, Russo IH, Ao X, Salicioni AM, Yang X, et al. S100P calcium-binding protein overexpression is associated with immortalization of human breast epithelial cells in vitro and early stages of breast cancer development in vivo. Int J Oncol 2000;16(2):231–240.
   PubMed Web of Science ®Google Scholar
• Bertram J, Palfner K, Hiddemann W, Kneba M. Elevated expression of S100P, CAPL and MAGE 3 in doxorubicin-resistant cell lines: comparison of mRNA differential display reverse transcription-polymerase chain reaction and subtractive suppressive hybridization for the analysis of differential gene expression. Anticancer Drugs 1998;9(4):311–317.
   PubMed Web of Science ®Google Scholar
• Averboukh L, Liang P, Kantoff PW, Pardee AB. Regulation of S100P expression by androgen. Prostate 1996;29(6):350–355.
   PubMed Web of Science ®Google Scholar
• Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8(8):816–824.
   PubMed Web of Science ®Google Scholar
• Shyu RY, Huang SL, Jiang SY. Retinoic acid increases expression of the calcium-binding protein S100P in human gastric cancer cells. J Biomed Sci 2003;10(3):313–319.
   PubMed Web of Science ®Google Scholar
• Hamada S, Satoh K, Hirota M, Kanno A, Ishida K, Umino J, et al. Calcium-binding protein S100P is a novel diagnostic marker of cholangiocarcinoma. Cancer Sci 2011;102(1):150–156.
   PubMed Web of Science ®Google Scholar
• Yoo HJ, Yun BR, Kwon JH, Ahn HS, Seol MA, Lee MJ, et al. Genetic and expression alterations in association with the sarcomatous change of cholangiocarcinoma cells. Exp Mol Med 2009;41(2):102–115.
   PubMed Web of Science ®Google Scholar
• Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003;63(10):2649–2657.
   PubMed Web of Science ®Google Scholar
• Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001;33(7):637–668.
   PubMed Web of Science ®Google Scholar
• Austermann J, Nazmi AR, Muller-Tidow C, Gerke V. Characterization of the Ca2+-regulated ezrin-S100P interaction and its role in tumor cell migration. J Biol Chem 2008;283(43):29331–29340.
   PubMed Web of Science ®Google Scholar
• Zhu L, Ito T, Nakahara T, Nagae K, Fuyuno Y, Nakao M, et al. Upregulation of S100P, receptor for advanced glycation end products and ezrin in malignant melanoma. J Dermatol 2013;40(12):973–979.
   PubMed Web of Science ®Google Scholar
• Mousses S, Bubendorf L, Wagner U, Hostetter G, Kononen J, Cornelison R, et al. Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res 2002;62(5):1256–1260.
   PubMed Web of Science ®Google Scholar
• Mousses S., Wagner U, Chen Y, Kim JW, Bubendorf L, Bittner M, et al. Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling. Oncogene 2001;20(46):6718–6723.
   PubMed Web of Science ®Google Scholar
• Basu GD, Azorsa DO, Kiefer JA, Rojas AM, Tuzmen S, Barrett MT, et al. Functional evidence implicating S100P in prostate cancer progression. Int J Cancer 2008;123(2):330–339.
   PubMed Web of Science ®Google Scholar
• Diederichs S, Bulk E, Steffen B, Ji P, Tickenbrock L, Lang K, et al. S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res 2004;64(16):5564–5569.
   PubMed Web of Science ®Google Scholar
• Bartling B, Rehbein G, Schmitt WD, Hofmann HS, Silber RE, Simm A, et al. S100A2-S100P expression profile and diagnosis of non-small cell lung carcinoma: impairment by advanced tumour stages and neoadjuvant chemotherapy. Eur J Cancer 2007;43(13):1935–1943.
   PubMed Web of Science ®Google Scholar
• Stern DM, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycationendproducts (RAGE) and the complications of diabetes. Ageing Res Rev 2002;1(1):1–15.
   PubMed Web of Science ®Google Scholar
• Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al. Blockade of RAGE-amphoterinsignalling suppresses tumour growth and metastases. Nature 2000;405(6784):354–360.
   PubMed Web of Science ®Google Scholar
• Heizmann CW, Fritz G, Schafer BW. S100 proteins: Structure, functions and pathology. Front Biosci 2002;7:d1356-d1368.
   PubMed Web of Science ®Google Scholar
• McNutt NS. The S100 family of multipurpose calcium-binding proteins. J Cutan Pathol 1998;25(10):521–529.
   PubMed Web of Science ®Google Scholar
• Kuramoto H, Tamura S, Notake Y. Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am J Obstet Gynecol 1972;114(8):1012–1019.
   PubMed Web of Science ®Google Scholar
• Fuentes MK, Nigavekar SS, Arumugam T, Logsdon CD, Schmidt AM, Park JC, et al. RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis Colon Rectum 2007;50(8):1230–1240.
   PubMed Web of Science ®Google Scholar
• Arumugam T, Ramachandran V, Logsdon CD. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst 2006;98(24):1806–1818.
   PubMedGoogle Scholar
• Riehl A, Nemeth J, Angel P, Hess J. The receptor RAGE: Bridging inflammation and cancer. Cell Commun Signal 2009;7:12.
   PubMed Web of Science ®Google Scholar
• Bianchi R, Kastrisianaki E, Giambanco I, Donato R. S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release. J BiolChem 2011;286(9):7214–7226.
   PubMed Web of Science ®Google Scholar
• Matsuzawa SI, Reed JC. Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol Cell 2001;7(5):915–926.
   PubMed Web of Science ®Google Scholar
• Filipek A. S100A6 and CacyBP/SIP - two proteins discovered in ehrlich ascites tumor cells that are potentially involved in the degradation of beta-catenin. Chemotherapy 2006;52(1):32–34.
   PubMed Web of Science ®Google Scholar
• Whiteman HJ, Weeks ME, Dowen SE, Barry S, Timms JF, Lemoine NR, et al. The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D. Cancer Res 2007;67(18):8633–8642.
   PubMed Web of Science ®Google Scholar
• Arumugam T, Simeone DM, Van Golen K, Logsdon CD. S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res 2005;11(15):5356–5364.
   PubMed Web of Science ®Google Scholar
• Kim JK, Jung KH, Noh JH, Eun JW, Bae HJ, Xie HJ, et al. Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma. Int J Oncol 2009;35(6):1257–1264.
   PubMed Web of Science ®Google Scholar